Nader Hirmas

1.2k total citations
38 papers, 738 citations indexed

About

Nader Hirmas is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nader Hirmas has authored 38 papers receiving a total of 738 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 17 papers in Radiology, Nuclear Medicine and Imaging and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nader Hirmas's work include Radiopharmaceutical Chemistry and Applications (15 papers), Peptidase Inhibition and Analysis (14 papers) and Prostate Cancer Treatment and Research (10 papers). Nader Hirmas is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (15 papers), Peptidase Inhibition and Analysis (14 papers) and Prostate Cancer Treatment and Research (10 papers). Nader Hirmas collaborates with scholars based in Germany, Jordan and United States. Nader Hirmas's co-authors include Wolfgang P. Fendler, Justin Ferdinandus, Lukas Kessler, Rainer Hamacher, Michael Nader, Lale Umutlu, Ken Herrmann, Akram Al‐Ibraheem, Manuel Weber and Fadi Zarrad and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Medicine.

In The Last Decade

Nader Hirmas

36 papers receiving 731 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nader Hirmas Germany	15	483	243	238	236	201	38	738
Zuoming Luo China	10	679 1.4×	258 1.1×	450 1.9×	438 1.9×	150 0.7×	16	880
Umut Elboğa Türkiye	11	255 0.5×	159 0.7×	149 0.6×	114 0.5×	159 0.8×	63	488
R. Tarabuzzi Italy	18	459 1.0×	198 0.8×	336 1.4×	163 0.7×	810 4.0×	42	1.2k
Zeynep Gözde Özkan Türkiye	14	243 0.5×	217 0.9×	111 0.5×	92 0.4×	121 0.6×	40	518
Meltem Ekenel Türkiye	13	297 0.6×	64 0.3×	117 0.5×	103 0.4×	282 1.4×	51	601
Duygu Has Şimşek Türkiye	13	275 0.6×	219 0.9×	101 0.4×	91 0.4×	183 0.9×	58	527
Shipra Agarwal India	13	199 0.4×	72 0.3×	207 0.9×	64 0.3×	99 0.5×	83	616
Kristine E. Kokeny United States	14	304 0.6×	102 0.4×	260 1.1×	409 1.7×	193 1.0×	40	812
Marilena Bellò Italy	15	308 0.6×	203 0.8×	229 1.0×	91 0.4×	235 1.2×	29	893

Countries citing papers authored by Nader Hirmas

Since Specialization

Citations

This map shows the geographic impact of Nader Hirmas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nader Hirmas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nader Hirmas more than expected).

Fields of papers citing papers by Nader Hirmas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nader Hirmas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nader Hirmas. The network helps show where Nader Hirmas may publish in the future.

Co-authorship network of co-authors of Nader Hirmas

This figure shows the co-authorship network connecting the top 25 collaborators of Nader Hirmas. A scholar is included among the top collaborators of Nader Hirmas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nader Hirmas. Nader Hirmas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fendler, Wolfgang P., Matthias Eiber, Boris Hadaschik, et al.. (2024). Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial). Journal of Nuclear Medicine. 65(7). 1076–1079. 5 indexed citations

Watanabe, Masao, Wolfgang P. Fendler, Hong Grafe, et al.. (2024). Prognostic Implications of⁶⁸Ga-FAPI-46 PET/CT–Derived Parameters on Overall Survival in Various Types of Solid Tumors. Journal of Nuclear Medicine. 65(7). 1027–1034. 9 indexed citations

Fendler, Wolfgang P., Matthias Eiber, Boris Hadaschik, et al.. (2024). Update from the PSMA-dRT trial: A randomized phase III trial of PSMA-PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer.. Journal of Clinical Oncology. 42(4_suppl). 291–291.

Pabst, Kim M., Marija Trajkovic‐Arsic, Phyllis F. Cheung, et al.. (2023). Superior Tumor Detection for⁶⁸Ga-FAPI-46 Versus¹⁸F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma. Journal of Nuclear Medicine. 64(7). 1049–1055. 32 indexed citations

Lückerath, Katharina, Jens T. Siveke, Benedikt M. Schaarschmidt, et al.. (2023). Novel Ga-68-FAPI PET/CT offers oncologic staging without COVID-19 vaccine-related pitfalls. Nuklearmedizin - NuclearMedicine. 62(2). 129–129. 2 indexed citations

Fendler, Wolfgang P., Kim M. Pabst, Rainer Hamacher, et al.. (2023). ⁶⁸Ga-FAPI-46 PET for cancer imaging: A prospective single-arm clinical trial.. Journal of Clinical Oncology. 41(16_suppl). 3064–3064. 1 indexed citations

Kessler, Lukas, Nader Hirmas, Kim M. Pabst, et al.. (2023). ⁶⁸Ga-Labeled Fibroblast Activation Protein Inhibitor (⁶⁸Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the⁶⁸Ga-FAPI PET Observational Trial. Journal of Nuclear Medicine. 64(12). 1910–1917. 13 indexed citations

Decker, Thomas, Nader Hirmas, Kristina Lübbe, et al.. (2023). Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA). The Breast. 72. 103575–103575. 4 indexed citations

Pabst, Kim M., Ken Herrmann, Christoph Rischpler, et al.. (2022). Thyroiditis: A pitfall in Ga-68-FAPI-PET/CT?. Nuklearmedizin - NuclearMedicine. 61(2). 195–195.

10.

Amayiri, Nisreen, Maisa Swaidan, Nader Hirmas, et al.. (2021). Molecular Subgroup Is the Strongest Predictor of Medulloblastoma Outcome in a Resource-Limited Country. JCO Global Oncology. 7(7). 1442–1453. 16 indexed citations

11.

Kessler, Lukas, Justin Ferdinandus, Nader Hirmas, et al.. (2021). Pitfalls and Common Findings in⁶⁸Ga-FAPI PET: A Pictorial Analysis. Journal of Nuclear Medicine. 63(6). 890–896. 72 indexed citations

12.

Al‐Ibraheem, Akram, Nader Hirmas, Stefano Fanti, et al.. (2021). Impact of 18F-FDG PET/CT, CT and EBUS/TBNA on preoperative mediastinal nodal staging of NSCLC. BMC Medical Imaging. 21(1). 49–49. 24 indexed citations

13.

Hirmas, Nader, Catherine Leyh, Miriam Sraieb, et al.. (2021). ⁶⁸Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma. Journal of Nuclear Medicine. 62(9). 1235–1241. 52 indexed citations

14.

Ferdinandus, Justin, Pedro Fragoso Costa, Lukas Kessler, et al.. (2021). Initial clinical experience with ⁹⁰Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients. Journal of Nuclear Medicine. 63(5). jnumed.121.262468–jnumed.121.262468. 91 indexed citations

15.

Farolfi, Andrea, Nader Hirmas, Andrei Gafita, et al.. (2020). Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study. Journal of Nuclear Medicine. 62(5). 675–678. 22 indexed citations

16.

Hirmas, Nader, et al.. (2020). 68Ga DOTA-TOC Uptake in Non-ossifying Fibroma: a Case Report. Nuclear Medicine and Molecular Imaging. 54(4). 199–203. 3 indexed citations

17.

Sraieb, Miriam, Nader Hirmas, Rupert Conrad, et al.. (2020). Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy. Medicine. 99(38). e22287–e22287. 4 indexed citations

18.

Hirmas, Nader, et al.. (2019). Hematologic markers of distant metastases and poor prognosis in gynecological cancers. BMC Cancer. 19(1). 141–141. 38 indexed citations

19.

Hirmas, Nader, Akram Al‐Ibraheem, Ken Herrmann, et al.. (2018). [68Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer. Molecular Imaging and Biology. 21(3). 574–581. 47 indexed citations

20.

Hirmas, Nader, et al.. (2018). Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives. Nuclear Medicine and Molecular Imaging. 52(3). 190–199. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact